TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01361295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI with PVAC gold
Description: Pulmonary vein isolation using the Medtronic PVAC gold catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI with Cooled-RF
Description: Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter
Study: NCT04309279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zentangle
Description: Zentangle is a mindful doodling process in which participants draw repetitive, structured patterns on small pieces of paper. The patterns consist of combinations of dots, lines, and curves.
Study: NCT03483558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: A standardized diet without any vegetables was provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinach
Description: A standardized diet with 200g spinach was provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Celery
Description: A standardized diet with 200g celery was provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onion
Description: A standardized diet with 200g onion was provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Vegetables
Description: A standardized diet with 200g of mixed vegetables (spinach, celery, and onion) was provided.
Study: NCT01535183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan combination chemotherapy
Description: Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min)~VCR 2㎎/㎡ d0 IV push~Etoposide 100㎎/㎡ d0-d2 IV over 1hr~Carboplatin 450㎎/㎡ d0 IV over 8hrs~Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna
Study: NCT00438321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole Pill

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01695577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary evaluation and VR
Description: Multidisciplinary assessment and evaluation and VR - Vestibular rehabilitation and balance training. Individually adjusted exercises in groups twice a week for two months. Home exercise program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary evaluation
Description: Multidisciplinary assessment and evaluation.
Study: NCT03670706

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Package of care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Package of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: analgesic optimisation
Description: optimisation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: analgesic optimisation
Description: optimisation
Study: NCT00281021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Digoxin
Description: Each subject will receive erlotinib and digoxin daily until progression.
Study: NCT03703245

Intervention type: OTHER
Intervention: Sodium bicarbonate
Description: Experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies.

Intervention type: OTHER
Intervention: Control Dentifrice
Description: Negative control dentifrice containing 0% w/w sodium bicarbonate
Study: NCT03382184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fraxel Dual laser
Description: The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halo laser
Description: The Halo hybrid laser will be used per protocol due to its dynamic thermal optimization technology for hair regrowth.
Study: NCT01224704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion
Description: Three percent saline (0.1ml/kg of the lean mass/min) will be infused for 120 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion
Description: Three percent saline (0.1ml/kg of the lean mass/min) will be infused for 120 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion
Description: Three percent saline (0.1ml/kg of the lean mass/min) will be infused for 120 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion
Description: Three percent saline (0.1ml/kg of the lean mass/min) will be infused for 120 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water deprivation
Description: 24 hour water deprivation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water deprivation
Description: 24 hour water deprivation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water deprivation
Description: 24 hour water deprivation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water deprivation
Description: 24 hour water deprivation
Study: NCT01744951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT
Description: ADAPT consists of the following modules/sessions:~Module 1: Trust, positive coping strategies, and behavior management; Module 2: Developmental understanding of adoption experience; Module 3: Substance abuse prevention; Module 4: Loss and grief issues about birth family and foster care; Module 5: Attachment/joining with adoptive family; Module 6: Search for identity/self -esteem; Module 7: Adoption and the outside world; Module 8: Trauma Treatment (if appropriate)
Study: NCT01800357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion of mildronate
Description: infusion of mildronate(500mg) once a day and for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: infusion of plabcebo once a day and for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: infusion of aspirin (100mg) once a day for days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aspirin
Description: infusion of aspirin (100mg) once a day for days
Study: NCT04337333

Intervention type: DEVICE
Group type: OTHER
Intervention: Two-in-one stent
Description: Endoscopic placement of a Two-in-one metal stent into extrahepatic bile duct
Study: NCT02300051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STPGP and RPGT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STPGP and RPGT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Study: NCT01107340

Intervention type: DEVICE
Group type: OTHER
Intervention: AMIStem Hip System
Study: NCT01008696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
Study: NCT04475367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App hypercross group
Description: hypertensive patients using HyperCrossApp
Study: NCT04914143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: broken Ganoderma lucidum spore powder
Description: The experimental group was treated with broken Ganoderma lucidum spore powder after chemotherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the control group was treated with placebo after chemotherapy
Study: NCT01176968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT04376970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLUCON®
Description: The drug was prescribed monthly according to the predefined regimen. It was not namely specefied in the prescription and was delivered by the hospital pharmacy according to the randomisation list.The subjects were masked to the contents and were instructed to return the empty tubes on monthly visit, wherein 1 pack of topical treatment was provided to them. Neither the patient nor the ophthalmologist knew the allocated treatment. No other medication was allowed during the trial. Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called  wash-out . Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A eye drops 0.5%
Description: The same regimen was prescribed for both treatments in order to preserve the double-blind characteristic. Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil, both sterilized by filtration. The preparation was carried out in a pharmacotechnical laboratory where a controlled atmosphere area was dedicated to ophthalmic preparations. The castor oil-Sandimmun® solution mixture is made in a sterile receptacle. After stirring, the mixture is distributed into sterile low density polyethylene bottles. A sterile insert and cap including a tamper-evident seal were placed on each bottle. A content control was then carried out on each batch produced. A sterility test was done on a batch of each day of preparation. Each bottle of each batch is then cleaned, polished, labeled and then packaged in a pre-printed box with an adapted notice. The stability was fixed at 6 months before opening and at 15 days after opening.
Study: NCT00966823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal tracheal obstruction with detachable balloon (device)
Description: Fetal tracheal obstruction with detachable balloon (device): Endoscopic placement of a detachable balloon in the fetal trachea at 28-30 weeks gestation.~- Ultrasound-guided puncture of balloon or, if not feasible, repeat endoscopic tracheoscopy with puncture and retrieval of the balloon at 34 weeks gestation.
Study: NCT04317560

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthrocentesis
Description: 2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrocentesis
Description: 2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injectable platelet rich fibrin injection
Description: 2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
Study: NCT04852263

Intervention type: OTHER
Group type: OTHER
Intervention: Group I
Description: Oral fiberoptic intubation was carried out using lingual traction without nasopharyngeal airway.

Intervention type: OTHER
Group type: OTHER
Intervention: Group II (NPA group)
Description: Oral fiberoptic intubation was carried out using lingual traction plus modified nasopharyngeal airway.
Study: NCT02431650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Study: NCT04888130

Intervention type: GENETIC
Intervention: Phylogenetic Analysis
Description: The phylogenetic analysis is carried out on a sample already taken in routine care (smear, culture on biopsy or PCR on swab).

Intervention type: OTHER
Intervention: Data collection
Description: Data will be collected using a standardized digital questionnaire, including clinical and microbiological features, treatments received details and training conditions and. Data will then be compared between patients with therapeutic success or failure.

Intervention type: OTHER
Intervention: Data collection
Description: Data will be collected using a standardized digital questionnaire, including clinical and microbiological features, treatments received details and training conditions and. Data will then be compared between patients with therapeutic success or failure.
Study: NCT01636414

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemovac drain
Description: The Hemovac drain is a device placed under your skin used to collect blood during surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-infusion drain
Description: This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic drain
Description: Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.
Study: NCT00518414

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Marketed infant formula with DHA and ARA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk-based infant formula with DHA and ARA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk-based formula with DHA, ARA, prebiotics
Study: NCT02885298

Intervention type: PROCEDURE
Intervention: Upright intubation
Description: Upright Intubation procedure performed with patient elevated above the supine position. Defined as upright greater to or equal to 45 degrees or inclined 10-44 degrees

Intervention type: PROCEDURE
Intervention: Upright intubation
Description: Upright Intubation procedure performed with patient elevated above the supine position. Defined as upright greater to or equal to 45 degrees or inclined 10-44 degrees

Intervention type: PROCEDURE
Intervention: Upright intubation
Description: Upright Intubation procedure performed with patient elevated above the supine position. Defined as upright greater to or equal to 45 degrees or inclined 10-44 degrees
Study: NCT00819286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SternaLock Rigid Fixation Plates
Description: patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wire (control)
Description: patients will have their sternum closed using wire (stainless steel surgical wire).
Study: NCT03239483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine gel
Description: Dapivirine gel (0.05%); administered rectally
Study: NCT04475367

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without App hypercross group
Description: Interdisciplinary health care
Study: NCT01035086

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fabricated food
Description: The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: fabricated food
Description: The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
Study: NCT03239483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Universal HEC placebo gel; administered rectally
Study: NCT02805049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinocandins
Description: The patients included in this protocol require routine treatment with caspofungin or micafungin. Though this intervention is under study, it is not modified by this protocol.
Study: NCT01949155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201
Description: Single, intratympanic injection
Study: NCT01035086

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fabricated food
Description: The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
Study: NCT04785313

Intervention type: BIOLOGICAL
Intervention: Retrievable Inferior Vena Cava Filters (IVCF)
Description: Analysis anatomopathology of Retrievable Inferior Vena Cava Filters (IVCF) (ALN CF model).
Study: NCT01949155

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Simulated single, intratympanic injection
Study: NCT04785313

Intervention type: OTHER
Intervention: Demographics data collection
Description: Demographics data : age, gender, thromboembolic risk factors, Retrievable Inferior Vena Cava Filters (IVCF) (indication, dates of insertion and removal), and anticoagulant management during the period with filter.
Study: NCT05379374

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine and morphine
Description: Bupivacaine group will receive 0.25% bupivacaine 20 ml in TAP block. Bupivacaine morphine group will receive 0.25% bupivacaine 20 ma with 3 mg morphine in TAP block.
Study: NCT02523560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based telerehabilitation
Description: Patients qualified to the study group will undergo, at five medical units a 9-week program of early hybrid, comprehensive cardiac telerehabilitation.
Study: NCT02887690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modular Prosthetic Limb
Study: NCT05703867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active microcurrent therapy
Description: Non-invasive transpalpebral microcurrent therapy delivery to the upper and lower eyelids
Study: NCT05379374

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: bupivacaine and morphine
Description: Bupivacaine group will receive 0.25% bupivacaine 20 ml in TAP block. Bupivacaine morphine group will receive 0.25% bupivacaine 20 ma with 3 mg morphine in TAP block.
Study: NCT02298582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal fentanyl
Description: During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
Study: NCT04116424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse training of the patient
Description: visit + telephone follow-up

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neurologist accompaniement
Description: presentation during consultation by neurologist
Study: NCT00418951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: 400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Description: 3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Description: 9 mg/kg intravenously once per week over 2 hours +/- 15 minutes
Study: NCT05251623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking program
Description: Subjects in PG walked to target steps daily with pedometer for 6 weeks